Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The monoclonal CCR5 antibody PRO-140: the promise of once-weekly HIV therapy.

Literature DB >> 21170687

The monoclonal CCR5 antibody PRO-140: the promise of once-weekly HIV therapy.

Allan R Tenorio¹.

Abstract

Entities: Gene

Year: 2011 PMID： 21170687 DOI： 10.1007/s11904-010-0068-y

Source DB: PubMed Journal: Curr HIV/AIDS Rep ISSN： 1548-3568 Impact factor: 5.071

× No keyword cloud information.

5 in total

1. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

Authors: Jeffrey M Jacobson; Jacob P Lalezari; Melanie A Thompson; Carl J Fichtenbaum; Michael S Saag; Barry S Zingman; Paul D'Ambrosio; Nancy Stambler; Yakov Rotshteyn; Andre J Marozsan; Paul J Maddon; Stephen A Morris; William C Olson
Journal: Antimicrob Agents Chemother Date: 2010-07-26 Impact factor: 5.191

2. Fixed-dose combinations improve medication compliance: a meta-analysis.

Authors: Sripal Bangalore; Gayathri Kamalakkannan; Sanobar Parkar; Franz H Messerli
Journal: Am J Med Date: 2007-08 Impact factor: 4.965

3. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

Authors: Camelia Protopopescu; François Raffi; Perrine Roux; Jacques Reynes; Pierre Dellamonica; Bruno Spire; Catherine Leport; Maria-Patrizia Carrieri
Journal: J Antimicrob Chemother Date: 2009-07-14 Impact factor: 5.790

4. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy.

Authors: Eva Poveda; Verónica Briz; Carmen de Mendoza; José Miguel Benito; Angélica Corral; Natalia Zahonero; Sara Lozano; Juan González-Lahoz; Vincent Soriano
Journal: J Med Virol Date: 2007-08 Impact factor: 2.327

5. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Authors: Jeffrey M Jacobson; Michael S Saag; Melanie A Thompson; Margaret A Fischl; Ralph Liporace; Richard C Reichman; Robert R Redfield; Carl J Fichtenbaum; Barry S Zingman; Mahesh C Patel; Jose D Murga; Suzanne M Pemrick; Paul D'Ambrosio; Marti Michael; Hans Kroger; Hieu Ly; Yakov Rotshteyn; Robert Buice; Stephen A Morris; Joseph J Stavola; Paul J Maddon; Alton B Kremer; William C Olson
Journal: J Infect Dis Date: 2008-11-01 Impact factor: 5.226

5 in total

3 in total

The monoclonal CCR5 antibody PRO-140: the promise of once-weekly HIV therapy.

1. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.

2. Fixed-dose combinations improve medication compliance: a meta-analysis.

3. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

4. Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy.

5. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.

Review 1. Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.

2. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.

3. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.